ProCE Banner Activity

BLC2001: Phase II Trial of FGFR Inhibitor Erdafitinib in Patients With FGFR-Altered Metastatic or Unresectable Urothelial Carcinoma

Slideset Download
Conference Coverage
This trial met its primary endpoint with an ORR of 40% and showed a manageable and well-tolerated safety profile for erdafitinib in FGFR-altered UC.

Released: June 12, 2018

Expiration: June 11, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen